These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 26801644)

  • 1. Low postoperative nonstimulated thyroglobulin as a criterion for the indication of low radioiodine activity in patients with papillary thyroid cancer of intermediate risk 'with higher risk features'.
    Rosario PW; Mourão GF; Calsolari MR
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):453-8. PubMed ID: 26801644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of adjuvant therapy with 3.7 GBq radioactive iodine in intermediate-risk patients with 'higher risk features' and predictive value of postoperative nonstimulated thyroglobulin.
    Rosario PW; Mourão GF; Calsolari MR
    Nucl Med Commun; 2016 Nov; 37(11):1148-53. PubMed ID: 27341413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation.
    Mourão GF; Rosario PW; Calsolari MR
    Endocr Relat Cancer; 2016 Jan; 23(1):47-52. PubMed ID: 26503963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of ablation with low radioiodine activity in patients with papillary thyroid carcinoma and predictive value of postoperative nonstimulated thyroglobulin.
    Rosario PW; Mourão GF; Calsolari MR
    Nucl Med Commun; 2016 Oct; 37(10):1024-9. PubMed ID: 27306852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A low postoperative nonstimulated serum thyroglobulin level excludes the presence of persistent disease in low-risk papillary thyroid cancer patients: implication for radioiodine indication.
    Rosario PW; Mourão GF; Siman TL; Calsolari MR
    Clin Endocrinol (Oxf); 2015 Dec; 83(6):957-61. PubMed ID: 25393656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can patients with papillary thyroid carcinoma and low postoperative thyroglobulin in the presence of clinically apparent lymph node metastases (cN1) be spared from radioiodine?
    Rosario PW; Mourão GF; Calsolari MR
    Endocrine; 2020 Dec; 70(3):552-557. PubMed ID: 32653994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Prates BS; Silva LC; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1140-3. PubMed ID: 23050786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
    Rosário PW; Calsolari MR
    Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indication for radioactive iodine in patients with papillary thyroid carcinoma without apparent disease after total thyroidectomy but with elevated antithyroglobulin antibodies.
    Ramos da Silva F; Rosario PW; Mourão GF
    Clin Endocrinol (Oxf); 2022 Jan; 96(1):82-88. PubMed ID: 34323308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
    Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
    Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Impact of Detectable Antithyroglobulin Antibodies Below the Reference Limit (Borderline) in Patients with Papillary Thyroid Carcinoma with Undetectable Serum Thyroglobulin and Normal Neck Ultrasonography After Ablation: A Prospective Study.
    Côrtes MCS; Rosario PW; Oliveira LFF; Calsolari MR
    Thyroid; 2018 Feb; 28(2):229-235. PubMed ID: 29325506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the follow-up of patients with papillary thyroid carcinoma of low and intermediate risk and excellent response to initial therapy be simplified using second-generation thyroglobulin assays?
    Rosario PW; Mourão GF; Calsolari MR
    Clin Endocrinol (Oxf); 2016 Oct; 85(4):596-601. PubMed ID: 26940991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
    Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and ¹³¹I activity in patients with thyroid cancer and low risk of recurrence.
    Rosario PW; Xavier AC; Calsolari MR
    Thyroid; 2011 Jan; 21(1):49-53. PubMed ID: 20954820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine.
    Rosario PW; Mourão G; Calsolari MR
    J Endocrinol Invest; 2019 Jun; 42(6):687-692. PubMed ID: 30353424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
    Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
    J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact factors for the outcome of the first
    Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
    Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent and recurrent disease in patients with papillary thyroid carcinoma with clinically apparent (cN1), but not extensive, lymph node involvement and without other factors for poor prognosis.
    Furtado Mde S; Rosario PW; Calsolari MR
    Arch Endocrinol Metab; 2015 Aug; 59(4):285-91. PubMed ID: 26331314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.
    Orlov S; Salari F; Kashat L; Freeman JL; Vescan A; Witterick IJ; Walfish PG
    Endocrine; 2015 Sep; 50(1):130-7. PubMed ID: 25792004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.